SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AES 2022 Annual Meeting

/PRNewswire/ -- SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing...

Related Keywords

China ,Japan ,United States ,Canada ,United Kingdom ,American ,Angelini Pharma ,Prnewswire Sk Life Science Inc ,Sk Group ,Source Sk Life Science Inc ,Sk Biopharmaceuticals Co Ltd ,American Epilepsy Society ,Epilepsy Foundation ,Sk Inc ,Sk Life Science Inc ,European Union ,Sudden Unexpected Death ,Annual Meeting ,Responder Rates Over ,Ono Pharmaceutical ,Ignis Therapeutics ,Greater China ,Familial Short ,North American Antiepileptic Drug ,Post Hoc Analysis ,Open Label Study ,Epilepsy During ,Cenobamate Clinical Development Program ,Who Gets ,Accessed March ,Sk Life Science ,Nc ,